Literature DB >> 21715627

Interplay between LXR and Wnt/β-catenin signaling in the negative regulation of peripheral myelin genes by oxysterols.

Joelle Makoukji1, Ghjuvan'Ghjacumu Shackleford, Delphine Meffre, Julien Grenier, Philippe Liere, Jean-Marc A Lobaccaro, Michael Schumacher, Charbel Massaad.   

Abstract

Oxysterols are reactive molecules generated from the oxidation of cholesterol. Their implication in cholesterol homeostasis and in the progression of neurodegenerative disorders is well known, but few data are available for their functions in the peripheral nervous system. Our aim was to study the influence of oxysterols on myelin gene expression and myelin sheath formation in peripheral nerves. We show by gas chromatography/mass spectrometry that Schwann cells and sciatic nerves contain 24(S)-hydroxycholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol and that they express their biosynthetic enzymes and receptors (liver X receptors LXRα and LXRβ). We demonstrate that oxysterols inhibit peripheral myelin gene expression [myelin protein zero (MPZ) and peripheral myelin protein-22 (PMP22)] in a Schwann cell line. This downregulation is mediated by either LXRα or LXRβ, depending on the promoter context, as suggested by siRNA strategy and chromatin immunoprecipitation assays in Schwann cells and in the sciatic nerve of LXR knock-out mice. Importantly, the knock-out of LXR in mice results in thinner myelin sheaths surrounding the axons. Oxysterols repress myelin genes via two mechanisms: by binding of LXRs to myelin gene promoters and by inhibiting the Wnt/β-catenin pathway that is crucial for the expression of myelin genes. The Wnt signaling components (Disheveled, TCF/LEF, β-catenin) are strongly repressed by oxysterols. Furthermore, the recruitment of β-catenin at the levels of the MPZ and PMP22 promoters is decreased. Our data reveal new endogenous mechanisms for the negative regulation of myelin gene expression, highlight the importance of oxysterols and LXR in peripheral nerve myelination, and open new perspectives of treating demyelinating diseases with LXR agonists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715627      PMCID: PMC6623163          DOI: 10.1523/JNEUROSCI.0761-11.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  40 in total

1.  Wnt/Rspondin/β-catenin signals control axonal sorting and lineage progression in Schwann cell development.

Authors:  Tamara Grigoryan; Simone Stein; Jingjing Qi; Hagen Wende; Alistair N Garratt; Klaus-Armin Nave; Carmen Birchmeier; Walter Birchmeier
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-22       Impact factor: 11.205

Review 2.  Negative regulators of schwann cell differentiation-novel targets for peripheral nerve therapies?

Authors:  André Heinen; Helmar C Lehmann; Patrick Küry
Journal:  J Clin Immunol       Date:  2012-09-06       Impact factor: 8.317

Review 3.  LXR agonists: new potential therapeutic drug for neurodegenerative diseases.

Authors:  Pei Xu; Dabing Li; Xiaotong Tang; Xiaohang Bao; Jing Huang; Yongping Tang; Yang Yang; Haiwei Xu; Xiaotang Fan
Journal:  Mol Neurobiol       Date:  2013-04-27       Impact factor: 5.590

4.  An innate immune response and altered nuclear receptor activation defines the spinal cord transcriptome during alpha-tocopherol deficiency in Ttpa-null mice.

Authors:  Carrie J Finno; Matthew H Bordbari; Giuliana Gianino; Brittni Ming-Whitfield; Erin Burns; Janel Merkel; Monica Britton; Blythe Durbin-Johnson; Erica A Sloma; Marissa McMackin; Gino Cortopassi; Victor Rivas; Marietta Barro; Cecilia K Tran; Ingrid Gennity; Hadi Habib; Libin Xu; Birgit Puschner; Andrew D Miller
Journal:  Free Radic Biol Med       Date:  2018-03-09       Impact factor: 7.376

5.  Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation.

Authors:  Gaia Cermenati; Federico Abbiati; Solei Cermenati; Elisabetta Brioschi; Alessandro Volonterio; Guido Cavaletti; Enrique Saez; Emma De Fabiani; Maurizio Crestani; Luis M Garcia-Segura; Roberto C Melcangi; Donatella Caruso; Nico Mitro
Journal:  J Lipid Res       Date:  2011-12-07       Impact factor: 5.922

Review 6.  Wnt and lithium: a common destiny in the therapy of nervous system pathologies?

Authors:  Delphine Meffre; Julien Grenier; Sophie Bernard; Françoise Courtin; Todor Dudev; Ghjuvan'Ghjacumu Shackleford; Mehrnaz Jafarian-Tehrani; Charbel Massaad
Journal:  Cell Mol Life Sci       Date:  2013-06-09       Impact factor: 9.261

7.  Involvement of Aryl hydrocarbon receptor in myelination and in human nerve sheath tumorigenesis.

Authors:  Ghjuvan'Ghjacumu Shackleford; Nirmal Kumar Sampathkumar; Mehdi Hichor; Laure Weill; Delphine Meffre; Ludmila Juricek; Ingrid Laurendeau; Aline Chevallier; Nicolas Ortonne; Frédérique Larousserie; Marc Herbin; Ivan Bièche; Xavier Coumoul; Mathieu Beraneck; Etienne-Emile Baulieu; Frédéric Charbonnier; Eric Pasmant; Charbel Massaad
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-19       Impact factor: 11.205

8.  Multi-omics investigation reveals benzalkonium chloride disinfectants alter sterol and lipid homeostasis in the mouse neonatal brain.

Authors:  Josi M Herron; Kelly M Hines; Hideaki Tomita; Ryan P Seguin; Julia Yue Cui; Libin Xu
Journal:  Toxicol Sci       Date:  2019-06-14       Impact factor: 4.849

Review 9.  Liver X receptors, nervous system, and lipid metabolism.

Authors:  G Cermenati; E Brioschi; F Abbiati; R C Melcangi; D Caruso; N Mitro
Journal:  J Endocrinol Invest       Date:  2013-04-18       Impact factor: 4.256

10.  Nuclear Receptor NR1H3 in Familial Multiple Sclerosis.

Authors:  Zhe Wang; A Dessa Sadovnick; Anthony L Traboulsee; Jay P Ross; Cecily Q Bernales; Mary Encarnacion; Irene M Yee; Madonna de Lemos; Talitha Greenwood; Joshua D Lee; Galen Wright; Colin J Ross; Si Zhang; Weihong Song; Carles Vilariño-Güell
Journal:  Neuron       Date:  2016-06-01       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.